{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T18:38:41Z","timestamp":1790102321891,"version":"4.0.1"},"reference-count":143,"publisher":"MDPI AG","issue":"7","license":[{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["IJMS"],"abstract":"<jats:p>Non-small-cell lung cancer (NSCLC) is the second most diagnosed type of malignancy and the first cause of cancer death worldwide. Despite recent advances, the treatment of choice for NSCLC patients remains to be chemotherapy, often showing very limited effectiveness with the frequent occurrence of drug-resistant phenotype and the lack of selectivity for tumor cells. Therefore, new effective and targeted therapeutics are needed. In this context, short RNA-based therapeutics, including Antisense Oligonucleotides (ASOs), microRNAs (miRNAs), short interfering (siRNA) and aptamers, represent a promising class of molecules. ASOs, miRNAs and siRNAs act by targeting and inhibiting specific mRNAs, thus showing an improved specificity compared to traditional anti-cancer drugs. Nucleic acid aptamers target and inhibit specific cancer-associated proteins, such as \u201cnucleic acid antibodies\u201d. Aptamers are also able of receptor-mediated cell internalization, and therefore, they can be used as carriers of secondary agents giving the possibility of producing very highly specific and effective therapeutics. This review provides an overview of the proposed applications of small RNAs for NSCLC treatment, highlighting their advantageous features and recent advancements in the field.<\/jats:p>","DOI":"10.3390\/ijms24076121","type":"journal-article","created":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T03:50:21Z","timestamp":1679629821000},"page":"6121","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":17,"title":["The Small RNA Landscape in NSCLC: Current Therapeutic Applications and Progresses"],"prefix":"10.3390","volume":"24","author":[{"given":"Giuseppe","family":"Ciccone","sequence":"first","affiliation":[{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS), National Research Council (CNR), 80145 Naples, Italy"},{"name":"Department of Environmental, Biological and Pharmaceutical Sciences and Technologies, University of Campania \u201cLuigi Vanvitelli\u201d, 81100 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria Luigia","family":"Ibba","sequence":"additional","affiliation":[{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS), National Research Council (CNR), 80145 Naples, Italy"},{"name":"Department of Precision Medicine, University of Campania \u201cLuigi Vanvitelli\u201d, 80138 Caserta, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gabriele","family":"Coppola","sequence":"additional","affiliation":[{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS), National Research Council (CNR), 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1653-4205","authenticated-orcid":false,"given":"Silvia","family":"Catuogno","sequence":"additional","affiliation":[{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS), National Research Council (CNR), 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Carla Lucia","family":"Esposito","sequence":"additional","affiliation":[{"name":"Institute of Experimental Endocrinology and Oncology \u201cGaetano Salvatore\u201d (IEOS), National Research Council (CNR), 80145 Naples, Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2023,3,24]]},"reference":[{"key":"ref_1","unstructured":"(2023, March 16). Cancer Facts & Figures 2022. American Cancer Society. Available online: https:\/\/www.cancer.org\/research\/cancer-facts-statistics\/all-cancer-facts-figures\/cancer-facts-figures-2022.html."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"138","DOI":"10.21037\/atm.2017.11.07","article-title":"The emerging treatment landscape of advanced non-small cell lung cancer","volume":"6","author":"Economopoulou","year":"2018","journal-title":"Ann. Transl. Med."},{"key":"ref_3","doi-asserted-by":"crossref","unstructured":"Park, K.H., Yang, J.-W., Kwon, J.-H., Lee, H., Yoon, Y.D., Choi, B.J., Lee, M.Y., Lee, C.W., Han, S.-B., and Kang, J.S. (2022). Targeted Induction of Endogenous VDUP1 by Small Activating RNA Inhibits the Growth of Lung Cancer Cells. Int. J. Mol. Sci., 23.","DOI":"10.3390\/ijms23147743"},{"key":"ref_4","doi-asserted-by":"crossref","unstructured":"Chernikov, I.V., Ponomareva, U.A., and Chernolovskaya, E.L. (2023). Structural Modifications of siRNA Improve Its Performance In Vivo. Int. J. Mol. Sci., 24.","DOI":"10.3390\/ijms24020956"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1186\/s12943-021-01338-2","article-title":"RNA-based therapies: A cog in the wheel of lung cancer defense","volume":"20","author":"Khan","year":"2021","journal-title":"Mol. Cancer"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1038\/s41573-020-0075-7","article-title":"Advances in oligonucleotide drug delivery","volume":"19","author":"Roberts","year":"2020","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"188377","DOI":"10.1016\/j.bbcan.2020.188377","article-title":"Nucleic acid nanotechnology for cancer treatment","volume":"1874","author":"Jin","year":"2020","journal-title":"Biochim. et Biophys. Acta Rev. Cancer"},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"16259","DOI":"10.1021\/acsomega.1c01755","article-title":"Liver-Targeted Delivery of Oligonucleotides with N-Acetylgalactosamine Conjugation","volume":"6","author":"Cui","year":"2021","journal-title":"ACS Omega"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1124\/pr.54.4.561","article-title":"Targeted Drug Delivery via the Transferrin Receptor-Mediated Endocytosis Pathway","volume":"54","author":"Qian","year":"2002","journal-title":"Pharmacol. Rev."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"105576","DOI":"10.1016\/j.ejps.2020.105576","article-title":"Diagnostic and therapeutic evaluation of folate-targeted paclitaxel and vinorelbine encapsulating theranostic liposomes for non-small cell lung cancer","volume":"156","author":"Karpuz","year":"2020","journal-title":"Eur. J. Pharm. Sci."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2034","DOI":"10.1093\/annonc\/mdv250","article-title":"Targeting the folate receptor: Diagnostic and therapeutic approaches to personalize cancer treatments","volume":"26","author":"Ledermann","year":"2015","journal-title":"Ann. Oncol."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1038\/s41576-021-00439-4","article-title":"Drug delivery systems for RNA therapeutics","volume":"23","author":"Paunovska","year":"2022","journal-title":"Nat. Rev. Genet."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"20031","DOI":"10.1038\/srep20031","article-title":"siRNAmod: A database of experimentally validated chemically modified siRNAs","volume":"6","author":"Dar","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1261\/rna.538907","article-title":"Effect of base modifications on structure, thermodynamic stability, and gene silencing activity of short interfering RNA","volume":"13","author":"Sipa","year":"2007","journal-title":"Rna"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"331","DOI":"10.3389\/fimmu.2017.00331","article-title":"RNA Interference-Induced Innate Immunity, Off-Target Effect, or Immune Adjuvant?","volume":"8","author":"Meng","year":"2017","journal-title":"Front. Immunol."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1038\/nm1191","article-title":"Sequence-specific potent induction of IFN-\u03b1 by short interfering RNA in plasmacytoid dendritic cells through TLR7","volume":"11","author":"Hornung","year":"2005","journal-title":"Nat. Med."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nbt1081","article-title":"Sequence-dependent stimulation of the mammalian innate immune response by synthetic siRNA","volume":"23","author":"Judge","year":"2005","journal-title":"Nat. Biotechnol."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1093\/intimm\/dxt040","article-title":"Chemical modifications on siRNAs avoid Toll-like-receptor-mediated activation of the hepatic immune system in vivo and in vitro","volume":"26","author":"Broering","year":"2013","journal-title":"Int. Immunol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"314ra185","DOI":"10.1126\/scitranslmed.aac5272","article-title":"AZD9150, a next-generation antisense oligonucleotide inhibitor of STAT3 with early evidence of clinical activity in lymphoma and lung cancer","volume":"7","author":"Hong","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1007\/s10637-005-6736-x","article-title":"Randomized phase II evaluation of aprinocarsen in combination with gemcitabine and cisplatin for patients with advanced\/metastatic non-small cell lung cancer","volume":"23","author":"Vansteenkiste","year":"2005","journal-title":"Investig. New Drugs"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"1239","DOI":"10.2217\/fon.12.129","article-title":"Custirsen (OGX-011): A second-generation antisense inhibitor of clusterin in development for the treatment of prostate cancer","volume":"8","author":"Zielinski","year":"2012","journal-title":"Futur. Oncol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"751","DOI":"10.1038\/nrd.2018.132","article-title":"An RNA toolbox for cancer immunotherapy","volume":"17","author":"Pastor","year":"2018","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"259","DOI":"10.1146\/annurev.pharmtox.010909.105654","article-title":"RNA Targeting Therapeutics: Molecular Mechanisms of Antisense Oligonucleotides as a Therapeutic Platform","volume":"50","author":"Bennett","year":"2010","journal-title":"Annu. Rev. Pharmacol. Toxicol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1089\/hum.2013.234","article-title":"Development of Therapeutic Splice-Switching Oligonucleotides","volume":"25","author":"Disterer","year":"2014","journal-title":"Hum. Gene Ther."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"3351","DOI":"10.1093\/nar\/gkw065","article-title":"RNA cleavage products generated by antisense oligonucleotides and siRNAs are processed by the RNA surveillance machinery","volume":"44","author":"Lima","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"17181","DOI":"10.1074\/jbc.M311683200","article-title":"Determination of the Role of the Human RNase H1 in the Pharmacology of DNA-like Antisense Drugs","volume":"279","author":"Wu","year":"2004","journal-title":"J. Biol. Chem."},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Dhuri, K., Bechtold, C., Quijano, E., Pham, H., Gupta, A., Vikram, A., and Bahal, R. (2020). Antisense Oligonucleotides: An Emerging Area in Drug Discovery and Development. J. Clin. Med., 9.","DOI":"10.3390\/jcm9062004"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1016\/j.jconrel.2022.10.050","article-title":"Nano drug delivery systems for antisense oligonucleotides (ASO) therapeutics","volume":"352","author":"Ramasamy","year":"2022","journal-title":"J. Control. Release"},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"e10374","DOI":"10.1002\/btm2.10374","article-title":"RNA therapeutics in the clinic","volume":"8","author":"Curreri","year":"2022","journal-title":"Bioeng. Transl. Med."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"4722","DOI":"10.1021\/acs.molpharmaceut.8b00696","article-title":"T7 Peptide-Conjugated Lipid Nanoparticles for Dual Modulation of Bcl-2 and Akt-1 in Lung and Cervical Carcinomas","volume":"15","author":"Cheng","year":"2018","journal-title":"Mol. Pharm."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"263","DOI":"10.1016\/j.omtn.2017.10.001","article-title":"Induced-Decay of Glycine Decarboxylase Transcripts as an Anticancer Therapeutic Strategy for Non-Small-Cell Lung Carcinoma","volume":"9","author":"Lin","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"951","DOI":"10.1111\/cas.14303","article-title":"ARL4C is associated with initiation and progression of lung adenocarcinoma and represents a therapeutic target","volume":"111","author":"Kimura","year":"2020","journal-title":"Cancer Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1186\/s12943-020-01217-2","article-title":"LINC00173.v1 promotes angiogenesis and progression of lung squamous cell carcinoma by sponging miR-511-5p to regulate VEGFA expression","volume":"19","author":"Chen","year":"2020","journal-title":"Mol. Cancer"},{"key":"ref_34","doi-asserted-by":"crossref","first-page":"1917","DOI":"10.1158\/1535-7163.MCT-17-1194","article-title":"STAT3 Cyclic Decoy Demonstrates Robust Antitumor Effects in Non\u2013Small Cell Lung Cancer","volume":"17","author":"Njatcha","year":"2018","journal-title":"Mol. Cancer Ther."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.cell.2013.09.041","article-title":"Systematic Identification of Molecular Subtype-Selective Vulnerabilities in Non-Small-Cell Lung Cancer","volume":"155","author":"Kim","year":"2013","journal-title":"Cell"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.critrevonc.2016.12.005","article-title":"Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity","volume":"110","author":"Matikas","year":"2017","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"eaal5253","DOI":"10.1126\/scitranslmed.aal5253","article-title":"Targeting KRAS-dependent tumors with AZD4785, a high-affinity therapeutic antisense oligonucleotide inhibitor of KRAS","volume":"9","author":"Ross","year":"2017","journal-title":"Sci. Transl. Med."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"e2113180119","DOI":"10.1073\/pnas.2113180119","article-title":"Targeting oncogenic KRAS with molecular brush-conjugated antisense oligonucleotides","volume":"119","author":"Wang","year":"2022","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/j.ccell.2015.04.010","article-title":"Small-Molecule Bcl2 BH4 Antagonist for Lung Cancer Therapy","volume":"27","author":"Han","year":"2015","journal-title":"Cancer Cell"},{"key":"ref_40","first-page":"3344","article-title":"Screening of the copy number increase of AKT in lung carcinoma by custom-designed MLPA","volume":"12","author":"Minegishi","year":"2019","journal-title":"Int. J. Clin. Exp. Pathol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s11095-016-2063-5","article-title":"Lipid Nanoparticles Loaded with an Antisense Oligonucleotide Gapmer Against Bcl-2 for Treatment of Lung Cancer","volume":"34","author":"Cheng","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"e055718","DOI":"10.1136\/bmjopen-2021-055718","article-title":"Safety, tolerability, pharmacokinetics and preliminary antitumour activity of an antisense oligonucleotide targeting STAT3 (danvatirsen) as monotherapy and in combination with durvalumab in Japanese patients with advanced solid malignancies: A phase 1 study","volume":"12","author":"Nishina","year":"2022","journal-title":"BMJ Open"},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/j.clml.2020.12.012","article-title":"A Phase 1b Study to Evaluate the Safety and Efficacy of Durvalumab in Combination With Tremelimumab or Danvatirsen in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma","volume":"21","author":"Ribrag","year":"2020","journal-title":"Clin. Lymphoma Myeloma Leuk."},{"key":"ref_44","first-page":"1454","article-title":"ISIS-3521. Isis Pharmaceuticals","volume":"2","author":"Li","year":"2001","journal-title":"Curr. Opin. Investig. Drugs"},{"key":"ref_45","unstructured":"Enna, S.J., and Bylund, D.B. (2008). xPharm: The Comprehensive Pharmacology Reference, Elsevier."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"17078","DOI":"10.1200\/jco.2006.24.18_suppl.17078","article-title":"Phase I study of OGX-011, a second generation antisense oligonucleotide (ASO) to clusterin, combined with cisplatin and gemcitabine as first-line treatment for patients with stage IIB\/IV non-small cell lung cancer (NSCLC)","volume":"24","author":"Laskin","year":"2006","journal-title":"J. Clin. Oncol."},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"7596","DOI":"10.1200\/jco.2007.25.18_suppl.7596","article-title":"A phase I\/II study of OGX-011 and a gemcitabine (GEM)\/platinum regimen as first-line therapy in 85 patients with advanced non-small cell lung cancer","volume":"25","author":"Laskin","year":"2007","journal-title":"J. Clin. Oncol."},{"key":"ref_48","doi-asserted-by":"crossref","first-page":"218169","DOI":"10.1155\/2014\/218169","article-title":"MicroRNAs-Role in Lung Cancer","volume":"2014","author":"Guz","year":"2014","journal-title":"Dis. Markers"},{"key":"ref_49","doi-asserted-by":"crossref","first-page":"581007","DOI":"10.3389\/fonc.2020.581007","article-title":"microRNAs Biogenesis, Functions and Role in Tumor Angiogenesis","volume":"10","author":"Annese","year":"2020","journal-title":"Front. Oncol."},{"key":"ref_50","first-page":"8029721","article-title":"Development of MicroRNAs as Potential Therapeutics against Cancer","volume":"2020","author":"Kamaruzman","year":"2020","journal-title":"J. Oncol."},{"key":"ref_51","doi-asserted-by":"crossref","first-page":"643942","DOI":"10.3389\/fcell.2021.643942","article-title":"Frontiers of MicroRNA Signature in Non-small Cell Lung Cancer","volume":"9","author":"Zhu","year":"2021","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_52","doi-asserted-by":"crossref","unstructured":"Reda El Sayed, S., Cristante, J., Guyon, L., Denis, J., Chabre, O., and Cherradi, N. (2021). MicroRNA Therapeutics in Cancer: Current Advances and Challenges. Cancers, 13.","DOI":"10.3390\/cancers13112680"},{"key":"ref_53","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.2217\/epi-2016-0035","article-title":"Clinical development of TargomiRs, a miRNA mimic-based treatment for patients with recurrent thoracic cancer","volume":"8","author":"Reid","year":"2016","journal-title":"Epigenomics"},{"key":"ref_54","doi-asserted-by":"crossref","unstructured":"Wani, J.A., Majid, S., Imtiyaz, Z., Rehman, M.U., Alsaffar, R.M., Shah, N.N., Alshehri, S., Ghoneim, M.M., and Imam, S.S. (2022). MiRNAs in Lung Cancer: Diagnostic, Prognostic, and Therapeutic Potential. Diagnostics, 12.","DOI":"10.3390\/diagnostics12071610"},{"key":"ref_55","doi-asserted-by":"crossref","first-page":"3539","DOI":"10.1007\/s00018-018-2877-x","article-title":"Overview upon miR-21 in lung cancer: Focus on NSCLC","volume":"75","author":"Magdo","year":"2018","journal-title":"Cell. Mol. Life Sci."},{"key":"ref_56","doi-asserted-by":"crossref","first-page":"932","DOI":"10.1007\/s13238-013-3092-z","article-title":"Microvesicle-delivery miR-150 promotes tumorigenesis by up-regulating VEGF, and the neutralization of miR-150 attenuate tumor development","volume":"4","author":"Liu","year":"2013","journal-title":"Protein Cell"},{"key":"ref_57","doi-asserted-by":"crossref","first-page":"3845","DOI":"10.1038\/onc.2008.6","article-title":"MicroRNA signatures of TRAIL resistance in human non-small cell lung cancer","volume":"27","author":"Garofalo","year":"2008","journal-title":"Oncogene"},{"key":"ref_58","doi-asserted-by":"crossref","first-page":"945","DOI":"10.3892\/ol.2015.4000","article-title":"miR-96 induces cisplatin chemoresistance in non-small cell lung cancer cells by downregulating SAMD9","volume":"11","author":"Wu","year":"2015","journal-title":"Oncol. Lett."},{"key":"ref_59","doi-asserted-by":"crossref","first-page":"9628","DOI":"10.1158\/0008-5472.CAN-05-2352","article-title":"A Polycistronic MicroRNA Cluster, miR-17-92, Is Overexpressed in Human Lung Cancers and Enhances Cell Proliferation","volume":"65","author":"Hayashita","year":"2005","journal-title":"Cancer Res."},{"key":"ref_60","doi-asserted-by":"crossref","first-page":"1056","DOI":"10.1038\/labinvest.2015.76","article-title":"MicroRNA-19 triggers epithelial\u2013mesenchymal transition of lung cancer cells accompanied by growth inhibition","volume":"95","author":"Li","year":"2015","journal-title":"Lab. Investig."},{"key":"ref_61","doi-asserted-by":"crossref","first-page":"7713","DOI":"10.1158\/0008-5472.CAN-07-1083","article-title":"The let-7 MicroRNA Represses Cell Proliferation Pathways in Human Cells","volume":"67","author":"Johnson","year":"2007","journal-title":"Cancer Res"},{"key":"ref_62","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/j.cell.2005.01.014","article-title":"RAS Is Regulated by the let-7 MicroRNA Family","volume":"120","author":"Johnson","year":"2005","journal-title":"Cell"},{"key":"ref_63","doi-asserted-by":"crossref","first-page":"3903","DOI":"10.1073\/pnas.0712321105","article-title":"Suppression of non-small cell lung tumor development by the let-7 microRNA family","volume":"105","author":"Kumar","year":"2008","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_64","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1101\/gad.1540407","article-title":"The tumor suppressor microRNA let-7 represses the HMGA2 oncogene","volume":"21","author":"Lee","year":"2007","journal-title":"Genes Dev."},{"key":"ref_65","doi-asserted-by":"crossref","first-page":"15805","DOI":"10.1073\/pnas.0707628104","article-title":"MicroRNA-29 family reverts aberrant methylation in lung cancer by targeting DNA methyltransferases 3A and 3B","volume":"104","author":"Fabbri","year":"2007","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_66","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.3892\/ijo.2016.3583","article-title":"Heterogeneous expression of zinc-finger E-box-binding homeobox 1 plays a pivotal role in metastasis via regulation of miR-200c in epithelial-mesenchymal transition","volume":"49","author":"Muto","year":"2016","journal-title":"Int. J. Oncol."},{"key":"ref_67","doi-asserted-by":"crossref","first-page":"25","DOI":"10.1158\/1541-7786.MCR-10-0497","article-title":"miR-200 Inhibits Lung Adenocarcinoma Cell Invasion and Metastasis by Targeting Flt1\/VEGFR1","volume":"9","author":"Roybal","year":"2011","journal-title":"Mol. Cancer Res."},{"key":"ref_68","doi-asserted-by":"crossref","first-page":"1630","DOI":"10.1038\/s41416-020-0802-1","article-title":"Phase 1 study of MRX34, a liposomal miR-34a mimic, in patients with advanced solid tumours","volume":"122","author":"Hong","year":"2020","journal-title":"Br. J. Cancer"},{"key":"ref_69","doi-asserted-by":"crossref","first-page":"9014","DOI":"10.1021\/acsami.6b02662","article-title":"Imaging Dendrimer-Grafted Graphene Oxide Mediated Anti-miR-21 Delivery With an Activatable Luciferase Reporter","volume":"8","author":"Wang","year":"2016","journal-title":"ACS Appl. Mater. Interfaces"},{"key":"ref_70","doi-asserted-by":"crossref","first-page":"39001","DOI":"10.1038\/srep39001","article-title":"MiR-150 promotes cellular metastasis in non-small cell lung cancer by targeting FOXO4","volume":"6","author":"Li","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_71","first-page":"50","article-title":"Circulating miRNA-30a and miRNA-221 as Novel Biomarkers for the Early Detection of Non-Small-Cell Lung Cancer","volume":"11","author":"Ghany","year":"2020","journal-title":"Middle East J. Cancer"},{"key":"ref_72","doi-asserted-by":"crossref","first-page":"6099","DOI":"10.1038\/sj.onc.1210425","article-title":"Apoptosis induction by antisense oligonucleotides against miR-17-5p and miR-20a in lung cancers overexpressing miR-17-92","volume":"26","author":"Matsubara","year":"2007","journal-title":"Oncogene"},{"key":"ref_73","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1002\/jso.23312","article-title":"Serum miR-19a expression correlates with worse prognosis of patients with non-small cell lung cancer","volume":"107","author":"Lin","year":"2013","journal-title":"J. Surg. Oncol."},{"key":"ref_74","doi-asserted-by":"crossref","unstructured":"Dai, X., Jiang, Y., and Tan, C. (2015). Let-7 Sensitizes KRAS Mutant Tumor Cells to Chemotherapy. PLoS ONE, 10.","DOI":"10.1371\/journal.pone.0126653"},{"key":"ref_75","doi-asserted-by":"crossref","first-page":"e12847","DOI":"10.1097\/MD.0000000000012847","article-title":"Predictive value of microRNA let-7a expression for efficacy and prognosis of radiotherapy in patients with lung cancer brain metastasis: A case-control study","volume":"97","author":"Liu","year":"2018","journal-title":"Medicine"},{"key":"ref_76","first-page":"495","article-title":"let-7 and miR-17 promote self-renewal and drive gefitinib resistance in non-small cell lung cancer","volume":"42","author":"Yin","year":"2019","journal-title":"Oncol. Rep."},{"key":"ref_77","doi-asserted-by":"crossref","first-page":"1151","DOI":"10.1038\/mt.2014.5","article-title":"Multifunctional Aptamer-miRNA Conjugates for Targeted Cancer Therapy","volume":"22","author":"Esposito","year":"2014","journal-title":"Mol. Ther."},{"key":"ref_78","doi-asserted-by":"crossref","first-page":"e84","DOI":"10.1038\/mtna.2013.14","article-title":"Therapeutic Delivery of MicroRNA-29b by Cationic Lipoplexes for Lung Cancer","volume":"2","author":"Wu","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_79","doi-asserted-by":"crossref","first-page":"111463","DOI":"10.1016\/j.colsurfb.2020.111463","article-title":"N-Isopropylacrylamide-modified polyethylenimine-mediated miR-29a delivery to inhibit the proliferation and migration of lung cancer cells","volume":"198","author":"Xing","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_80","doi-asserted-by":"crossref","first-page":"1109","DOI":"10.1101\/gad.347344.120","article-title":"miR-200 deficiency promotes lung cancer metastasis by activating Notch signaling in cancer-associated fibroblasts","volume":"35","author":"Xue","year":"2021","journal-title":"Genes Dev."},{"key":"ref_81","doi-asserted-by":"crossref","unstructured":"Tejero-Villalba, R., Navarro, A., Campayo, M., Vi\u00f1olas, N., Marrades, R.M., Cordeiro, A., Ru\u00edz-Mart\u00ednez, M., Santasusagna, S., Molins, L., and Ramirez, J. (2014). miR-141 and miR-200c as Markers of Overall Survival in Early Stage Non-Small Cell Lung Cancer Adenocarcinoma. PLoS ONE, 9.","DOI":"10.1371\/journal.pone.0101899"},{"key":"ref_82","doi-asserted-by":"crossref","first-page":"1494","DOI":"10.1038\/mt.2014.79","article-title":"Therapeutic Delivery of miR-200c Enhances Radiosensitivity in Lung Cancer","volume":"22","author":"Cortez","year":"2014","journal-title":"Mol. Ther. J. Am. Soc. Gene Ther."},{"key":"ref_83","doi-asserted-by":"crossref","first-page":"1130","DOI":"10.1038\/nature05939","article-title":"A microRNA component of the p53 tumour suppressor network","volume":"447","author":"He","year":"2007","journal-title":"Nature"},{"key":"ref_84","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1186\/s13046-019-1059-5","article-title":"MicroRNA-34 family: A potential tumor suppressor and therapeutic candidate in cancer","volume":"38","author":"Zhang","year":"2019","journal-title":"J. Exp. Clin. Cancer Res."},{"key":"ref_85","doi-asserted-by":"crossref","first-page":"193","DOI":"10.1038\/cdd.2009.56","article-title":"The miR-34 family in cancer and apoptosis","volume":"17","author":"Hermeking","year":"2009","journal-title":"Cell Death Differ."},{"key":"ref_86","doi-asserted-by":"crossref","first-page":"106168","DOI":"10.1016\/j.biocel.2022.106168","article-title":"microRNA-34 family: From mechanism to potential applications","volume":"144","author":"Wang","year":"2022","journal-title":"Int. J. Biochem. Cell Biol."},{"key":"ref_87","doi-asserted-by":"crossref","first-page":"5576","DOI":"10.1158\/0008-5472.CAN-12-2001","article-title":"miRNA-34 Prevents Cancer Initiation and Progression in a Therapeutically Resistant K-ras and p53-Induced Mouse Model of Lung Adenocarcinoma","volume":"72","author":"Kasinski","year":"2012","journal-title":"Cancer Res"},{"key":"ref_88","doi-asserted-by":"crossref","first-page":"426","DOI":"10.1038\/nature07758","article-title":"The promises and pitfalls of RNA-interference-based therapeutics","volume":"457","author":"Castanotto","year":"2009","journal-title":"Nature"},{"key":"ref_89","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1038\/nrd2310","article-title":"Interfering with disease: A progress report on siRNA-based therapeutics","volume":"6","author":"Vornlocher","year":"2007","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_90","doi-asserted-by":"crossref","first-page":"343","DOI":"10.1038\/nature02873","article-title":"Mechanisms of gene silencing by double-stranded RNA","volume":"431","author":"Meister","year":"2004","journal-title":"Nature"},{"key":"ref_91","doi-asserted-by":"crossref","first-page":"806","DOI":"10.1038\/35888","article-title":"Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans","volume":"391","author":"Fire","year":"1998","journal-title":"Nature"},{"key":"ref_92","doi-asserted-by":"crossref","first-page":"114432","DOI":"10.1016\/j.bcp.2021.114432","article-title":"The growth of siRNA-based therapeutics: Updated clinical studies","volume":"189","author":"Zhang","year":"2021","journal-title":"Biochem. Pharmacol."},{"key":"ref_93","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1056\/NEJMoa1716153","article-title":"Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis","volume":"379","author":"Adams","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"ref_94","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1007\/s40265-020-01269-0","article-title":"Givosiran: First Approval","volume":"80","author":"Scott","year":"2020","journal-title":"Drugs"},{"key":"ref_95","doi-asserted-by":"crossref","first-page":"1216","DOI":"10.1056\/NEJMoa2021712","article-title":"Lumasiran, an RNAi Therapeutic for Primary Hyperoxaluria Type 1","volume":"384","author":"Garrelfs","year":"2021","journal-title":"New Engl. J. Med."},{"key":"ref_96","doi-asserted-by":"crossref","unstructured":"Kosmas, C.E., Mu\u00f1oz Estrella, A., Sourlas, A., Silverio, D., Hilario, E., Montan, P.D., and Guzman, E. (2018). Inclisiran: A New Promising Agent in the Management of Hypercholesterolemia. Diseases, 6.","DOI":"10.3390\/diseases6030063"},{"key":"ref_97","doi-asserted-by":"crossref","first-page":"644718","DOI":"10.3389\/fphar.2021.644718","article-title":"Insight Into the Prospects for RNAi Therapy of Cancer","volume":"12","author":"Tian","year":"2021","journal-title":"Front. Pharmacol."},{"key":"ref_98","doi-asserted-by":"crossref","first-page":"5917","DOI":"10.1158\/1538-7445.AM2018-5917","article-title":"Abstract 5917: A novel lipid nanoparticle (NBF-006) encapsulating glutathione S-transferase P (GSTP) siRNA for the treatment of KRAS-driven non-small cell lung cancer","volume":"78","author":"Wang","year":"2018","journal-title":"Cancer Res"},{"key":"ref_99","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1080\/07357907.2017.1416393","article-title":"Potential Molecular Targets in the Treatment of Lung Cancer Using siRNA Technology","volume":"36","author":"Zarredar","year":"2018","journal-title":"Cancer Investig."},{"key":"ref_100","first-page":"187","article-title":"Role of epidermal growth factor receptor in lung cancer and targeted therapies","volume":"7","author":"Liu","year":"2017","journal-title":"Am. J. Cancer Res."},{"key":"ref_101","doi-asserted-by":"crossref","first-page":"28","DOI":"10.1186\/1741-7015-10-28","article-title":"Targeting the epidermal growth factor receptor in non-small cell lung cancer cells: The effect of combining RNA interference with tyrosine kinase inhibitors or cetuximab","volume":"10","author":"Chen","year":"2012","journal-title":"BMC Med."},{"key":"ref_102","doi-asserted-by":"crossref","first-page":"8362","DOI":"10.7150\/thno.39816","article-title":"Strategy to enhance lung cancer treatment by five essential elements: Inhalation delivery, nanotechnology, tumor-receptor targeting, chemo- and gene therapy","volume":"9","author":"Garbuzenko","year":"2019","journal-title":"Theranostics"},{"key":"ref_103","doi-asserted-by":"crossref","first-page":"102007","DOI":"10.1016\/j.nano.2019.04.010","article-title":"Silencing AXL by covalent siRNA-gelatin-antibody nanoconjugate inactivates mTOR\/EMT pathway and stimulates p53 for TKI sensitization in NSCLC","volume":"20","author":"Suresh","year":"2019","journal-title":"Nanomedicine"},{"key":"ref_104","doi-asserted-by":"crossref","first-page":"67","DOI":"10.2147\/LCTT.S305484","article-title":"Targeting AXL in NSCLC","volume":"12","author":"Zaman","year":"2021","journal-title":"Lung Cancer Targets Ther."},{"key":"ref_105","doi-asserted-by":"crossref","first-page":"E3553","DOI":"10.1073\/pnas.1412686111","article-title":"Small RNA combination therapy for lung cancer","volume":"111","author":"Xue","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"key":"ref_106","doi-asserted-by":"crossref","first-page":"30245","DOI":"10.1038\/srep30245","article-title":"Targeted nanoconjugate co-delivering siRNA and tyrosine kinase inhibitor to KRAS mutant NSCLC dissociates GAB1-SHP2 post oncogene knockdown","volume":"6","author":"Srikar","year":"2016","journal-title":"Sci. Rep."},{"key":"ref_107","doi-asserted-by":"crossref","first-page":"15330338211041453","DOI":"10.1177\/15330338211041453","article-title":"Cetuximab\u2013siRNA Conjugate Linked Through Cationized Gelatin Knocks Down KRAS G12C Mutation in NSCLC Sensitizing the Cells Toward Gefitinib","volume":"20","author":"Sreedurgalakshmi","year":"2021","journal-title":"Technol. Cancer Res. Treat."},{"key":"ref_108","doi-asserted-by":"crossref","first-page":"3515","DOI":"10.1021\/mp5002894","article-title":"Mad2 Checkpoint Gene Silencing Using Epidermal Growth Factor Receptor-Targeted Chitosan Nanoparticles in Non-Small Cell Lung Cancer Model","volume":"11","author":"Nascimento","year":"2014","journal-title":"Mol. Pharm."},{"key":"ref_109","doi-asserted-by":"crossref","first-page":"e110","DOI":"10.1038\/mtna.2013.29","article-title":"Combination of siRNA-directed Gene Silencing With Cisplatin Reverses Drug Resistance in Human Non-small Cell Lung Cancer","volume":"2","author":"Ganesh","year":"2013","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_110","doi-asserted-by":"crossref","first-page":"2943","DOI":"10.1007\/s11095-016-2016-z","article-title":"Enhanced Anti-Tumor Efficacy of Lipid-Modified Platinum Derivatives in Combination with Survivin Silencing siRNA in Resistant Non-Small Cell Lung Cancer","volume":"33","author":"Mattheolabakis","year":"2016","journal-title":"Pharm. Res."},{"key":"ref_111","doi-asserted-by":"crossref","first-page":"111105","DOI":"10.1016\/j.colsurfb.2020.111105","article-title":"Reduction sensitive nanocarriers mPEG-g-\u03b3-PGA\/SSBPEI@siRNA for effective targeted delivery of survivin siRNA against NSCLC","volume":"193","author":"Chenab","year":"2020","journal-title":"Colloids Surf. B Biointerfaces"},{"key":"ref_112","doi-asserted-by":"crossref","first-page":"36","DOI":"10.1007\/s12032-021-01626-3","article-title":"SOX2 knockdown with siRNA reverses cisplatin resistance in NSCLC by regulating APE1 signaling","volume":"39","author":"Chen","year":"2022","journal-title":"Med. Oncol."},{"key":"ref_113","doi-asserted-by":"crossref","first-page":"2353","DOI":"10.1016\/j.ejca.2011.05.006","article-title":"RNAi-mediated silencing of VEGF-C inhibits non-small cell lung cancer progression by simultaneously down-regulating the CXCR4, CCR7, VEGFR-2 and VEGFR-3-dependent axes-induced ERK, p38 and AKT signalling pathways","volume":"47","author":"Feng","year":"2011","journal-title":"Eur. J. Cancer"},{"key":"ref_114","doi-asserted-by":"crossref","first-page":"2280","DOI":"10.1021\/mp300152v","article-title":"Nanoparticle Delivery of Pooled siRNA for Effective Treatment of Non-Small Cell Lung Caner","volume":"9","author":"Yang","year":"2012","journal-title":"Mol. Pharm."},{"key":"ref_115","doi-asserted-by":"crossref","first-page":"5886","DOI":"10.7150\/thno.32416","article-title":"Co-delivery of VEGF siRNA and Etoposide for Enhanced Anti-angiogenesis and Anti-proliferation Effect via Multi-functional Nanoparticles for Orthotopic Non-Small Cell Lung Cancer Treatment","volume":"9","author":"Li","year":"2019","journal-title":"Theranostics"},{"key":"ref_116","doi-asserted-by":"crossref","first-page":"63","DOI":"10.5732\/cjc.012.10098","article-title":"The genetics and biology of KRAS in lung cancer","volume":"32","author":"Westcott","year":"2013","journal-title":"Chin. J. Cancer"},{"key":"ref_117","doi-asserted-by":"crossref","first-page":"1513","DOI":"10.1097\/JTO.0000000000000305","article-title":"KRAS-G12C Mutation Is Associated with Poor Outcome in Surgically Resected Lung Adenocarcinoma","volume":"9","author":"Nadal","year":"2014","journal-title":"J. Thorac. Oncol."},{"key":"ref_118","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1016\/j.ijpharm.2016.03.062","article-title":"Highly stable polyglutamate derivatives\/siRNA polyplex efficiently down-relegate survivin expression and augment the efficacy of cisplatin","volume":"505","author":"Wang","year":"2016","journal-title":"Int. J. Pharm."},{"key":"ref_119","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1007\/s11912-015-0448-y","article-title":"The Role of Anti-angiogenesis in Non-small-cell Lung Cancer: An Update","volume":"17","author":"Villaruz","year":"2015","journal-title":"Curr. Oncol. Rep."},{"key":"ref_120","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1038\/346818a0","article-title":"In vitro selection of RNA molecules that bind specific ligands","volume":"346","author":"Ellington","year":"1990","journal-title":"Nature"},{"key":"ref_121","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1126\/science.2200121","article-title":"Systematic Evolution of Ligands by Exponential Enrichment: RNA Ligands to Bacteriophage T4 DNA Polymerase","volume":"249","author":"Tuerk","year":"1990","journal-title":"Science"},{"key":"ref_122","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.2147\/IJN.S237544","article-title":"Aptamers as Versatile Ligands for Biomedical and Pharmaceutical Applications","volume":"15","author":"Guan","year":"2020","journal-title":"Int. J. Nanomed."},{"key":"ref_123","doi-asserted-by":"crossref","unstructured":"Fu, Z., and Xiang, J. (2020). Aptamers, the Nucleic Acid Antibodies, in Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21082793"},{"key":"ref_124","doi-asserted-by":"crossref","unstructured":"Catuogno, S., Esposito, C., and De Franciscis, V. (2016). Aptamer-Mediated Targeted Delivery of Therapeutics: An Update. Pharmaceuticals, 9.","DOI":"10.3390\/ph9040069"},{"key":"ref_125","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/nrd.2016.199","article-title":"Aptamers as targeted therapeutics: Current potential and challenges","volume":"16","author":"Zhou","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"ref_126","doi-asserted-by":"crossref","unstructured":"Esposito, C., Passaro, D., Longobardo, I., Condorelli, G., Marotta, P., Affuso, A., De Franciscis, V., and Cerchia, L. (2011). A Neutralizing RNA Aptamer against EGFR Causes Selective Apoptotic Cell Death. PLoS ONE, 6.","DOI":"10.1371\/journal.pone.0024071"},{"key":"ref_127","doi-asserted-by":"crossref","first-page":"2291","DOI":"10.1038\/mt.2012.163","article-title":"Targeting Axl With an High-affinity Inhibitory Aptamer","volume":"20","author":"Cerchia","year":"2012","journal-title":"Mol. Ther."},{"key":"ref_128","doi-asserted-by":"crossref","first-page":"187","DOI":"10.1016\/j.omtn.2017.12.003","article-title":"In Vivo SELEX of an Inhibitory NSCLC-Specific RNA Aptamer from PEGylated RNA Library","volume":"10","author":"Wang","year":"2017","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_129","doi-asserted-by":"crossref","first-page":"5242","DOI":"10.1166\/jnn.2018.15424","article-title":"Promoted Delivery of Salinomycin to Lung Cancer Through Epidermal Growth Factor Receptor Aptamers Coupled DSPE-PEG2000 Nanomicelles","volume":"18","author":"Leng","year":"2018","journal-title":"J. Nanosci. Nanotechnol."},{"key":"ref_130","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1089\/nat.2021.0002","article-title":"Non-Small-Cell Lung Cancer Regression by siRNA Delivered Through Exosomes That Display EGFR RNA Aptamer","volume":"31","author":"Li","year":"2021","journal-title":"Nucleic Acid Ther."},{"key":"ref_131","doi-asserted-by":"crossref","first-page":"e289","DOI":"10.1038\/mtna.2016.5","article-title":"Aptamer-miRNA-212 Conjugate Sensitizes NSCLC Cells to TRAIL","volume":"5","author":"Iaboni","year":"2016","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_132","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1016\/j.omtn.2018.09.016","article-title":"Aptamer-miR-34c Conjugate Affects Cell Proliferation of Non-Small-Cell Lung Cancer Cells","volume":"13","author":"Russo","year":"2018","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_133","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1016\/j.omtn.2019.06.002","article-title":"Axl-Targeted Delivery of the Oncosuppressor miR-137 in Non-small-Cell Lung Cancer","volume":"17","author":"Nuzzo","year":"2019","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"ref_134","first-page":"1864","article-title":"Development of docetaxel liposome surface modified with CD133 aptamers for lung cancer targeting","volume":"46","author":"Ma","year":"2018","journal-title":"Artif. Cells Nanomed. Biotechnol."},{"key":"ref_135","first-page":"192","article-title":"Dual-targeting nanomicelles with CD133 and CD44 aptamers for enhanced delivery of gefitinib to two populations of lung cancer-initiating cells","volume":"19","author":"Huang","year":"2019","journal-title":"Exp. Ther. Med."},{"key":"ref_136","doi-asserted-by":"crossref","unstructured":"Wei, Z., Zhou, Y., Wang, R., Wang, J., and Chen, Z. (2022). Aptamers as Smart Ligands for Targeted Drug Delivery in Cancer Therapy. Pharmaceutics, 14.","DOI":"10.3390\/pharmaceutics14122561"},{"key":"ref_137","doi-asserted-by":"crossref","unstructured":"Fu, Z., and Xiang, J. (2020). Aptamer-Functionalized Nanoparticles in Targeted Delivery and Cancer Therapy. Int. J. Mol. Sci., 21.","DOI":"10.3390\/ijms21239123"},{"key":"ref_138","doi-asserted-by":"crossref","first-page":"655","DOI":"10.1039\/C9TB02284H","article-title":"An anticancer agent-loaded PLGA nanomedicine with glutathione-response and targeted delivery for the treatment of lung cancer","volume":"8","author":"Zhang","year":"2019","journal-title":"J. Mater. Chem. B"},{"key":"ref_139","doi-asserted-by":"crossref","first-page":"1010428317695035","DOI":"10.1177\/1010428317695035","article-title":"Salinomycin: A new paradigm in cancer therapy","volume":"39","author":"Dewangan","year":"2017","journal-title":"Tumor Biol."},{"key":"ref_140","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1186\/s12951-018-0403-9","article-title":"Recent advancements in the use of exosomes as drug delivery systems","volume":"16","author":"Bunggulawa","year":"2018","journal-title":"J. Nanobiotechnology"},{"key":"ref_141","doi-asserted-by":"crossref","first-page":"1067861","DOI":"10.3389\/fcell.2023.1067861","article-title":"ROS production in response to high-power microwave pulses induces p53 activation and DNA damage in brain cells: Radiosensitivity and biological dosimetry evaluation","volume":"11","author":"Rana","year":"2023","journal-title":"Front. Cell Dev. Biol."},{"key":"ref_142","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1089\/nat.2022.0004","article-title":"Delivery of RNA Therapeutics: The Great Endosomal Escape!","volume":"32","author":"Dowdy","year":"2022","journal-title":"Nucleic Acid Ther."},{"key":"ref_143","doi-asserted-by":"crossref","first-page":"114113","DOI":"10.1016\/j.addr.2022.114113","article-title":"RNAi-based therapeutics and tumor targeted delivery in cancer","volume":"182","author":"Kara","year":"2022","journal-title":"Adv. Drug Deliv. Rev."}],"container-title":["International Journal of Molecular Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6121\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T19:01:59Z","timestamp":1760122919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1422-0067\/24\/7\/6121"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,3,24]]},"references-count":143,"journal-issue":{"issue":"7","published-online":{"date-parts":[[2023,4]]}},"alternative-id":["ijms24076121"],"URL":"https:\/\/doi.org\/10.3390\/ijms24076121","relation":{},"ISSN":["1422-0067"],"issn-type":[{"value":"1422-0067","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,3,24]]}}}